395 – Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease, & more
In a Nutshell
The brain produces and manages all its own cholesterol independently of plasma levels, using astrocytes to synthesize it and APOE-containing HDL-like particles to deliver it to neurons via the matriosome. APOE4 impairs this delivery, disrupts membrane cholesterol balance, and increases amyloid-beta 42 production, elevating Alzheimer's risk, while excess neuronal cholesterol is eliminated as 24S-hydroxycholesterol. Statins and CETP inhibitors can modulate brain cholesterol synthesis and enhance protective apoA1 transport across the blood-brain barrier, respectively, offering potential therapeutic avenues when monitored via desmosterol and oxysterol biomarkers.
These notes were generated by AI and may contain inaccuracies.
Peter Attia welcomes Tom Dayspring back to discuss cholesterol in the brain, noting this has become an enormous passion and area of curiosity. They begin with foundational knowledge about lipids to ensure everyone starts from the same baseline.
Cholesterol is essential for human life and is used for making critical molecules, but its most important function is positioning itself in cell membranes throughout the body. Cell membranes regulate integrity and control what enters and exits cells. Evolution has given every cell in the body the ability to de novo synthesize the cholesterol it needs. Each cell needs only a minor number of cholesterol molecules, but if a cell over-synthesizes or accumulates excess cholesterol, the cholesterol can crystallize, which is toxic to the cell and will kill it.
Evolution has given cells the ability to export excess cholesterol out of the cytosol into plasma. However, lipids are hydrophobic and cannot circulate freely in plasma, which is an aqueous solution. Evolution solved this by providing proteins that bind to lipids and wrap them into particles called lipoproteins, allowing lipids including cholesterol and triglycerides to circulate in the bloodstream.
When a cell fluxes cholesterol out, it joins with a protein called APOA1, the structural protein of high-density lipoproteins (HDLs). HDLs accept cholesterol from any cell in the body that is effluxing it. The apoB family of lipoproteins are much bigger than HDLs and are produced in the liver, with one type produced in the small intestine. The structural protein of apoB lipoproteins is the very large peptide called apolipoprotein B.
The intestine makes a full-size apoB100 and a truncated version called apoB48, which has 48% of the molecular weight of apoB100. The intestine produces chylomicrons in apoB48 particles, which are very transient postprandial particles that traffic absorbed fatty acids (which become triglycerides) and absorbed cholesterol into the bloodstream.
The liver manufactures apoB particles including very low-density lipoproteins (VLDLs), which are quite big because they pack triglycerides that they transport primarily to muscles and fat cells before returning to the liver. As VLDLs lose triglycerides, they shrink and become VLDL remnants, then intermediate-density lipoproteins (IDLs), which rapidly become low-density lipoproteins (LDLs). The liver also has the ability to de novo manufacture and secrete LDLs directly.
LDLs have two sources: they are the product of VLDL catabolism or they are produced directly by the liver. ApoB particles carry a lot of lipid cargo, with triglycerides primarily in VLDLs. LDL is primarily a cholesterol-carrying particle with minimal triglycerides, but it has the longest plasma residence time of anything in the apoB family, lasting three to four or even five days in some circumstances.
Ultimately, LDLs get cleared by the liver through LDL receptors that bind to apoB particles and pull them into the liver, where the liver digests them. LDLs interact with HDLs in ways that are not well recognized. Approximately 90% of all lipoproteins in the body are HDLs, with the remainder being the apoB family. However, the apoB family traffics far more lipids because of their larger size, since the volume of a sphere is the cube of the radius.
After HDLs accept cholesterol from cells, they become mature HDLs. HDLs can deliver cholesterol to steroidogenic tissues that make cortisone or gonadal hormones, to adipocytes (the cholesterol storage organ), or return it to the liver and even the small intestine. A major function of HDLs is transferring cholesterol mass into apoB particles, primarily LDLs, due to LDLs' long plasma residence time.
The traditional teaching is that HDLs perform reverse cholesterol transport by bringing cholesterol back to the liver or gut. However, when HDLs transfer cholesterol to LDLs, the HDL becomes smaller and can start its journey again, while the LDL returns the cholesterol to the liver. This creates indirect reverse cholesterol transport via LDLs, in addition to direct reverse cholesterol transport by HDLs. Total reverse cholesterol transport is the sum of both pathways.
The primary function of LDLs is to return cholesterol to the liver. The idea that LDLs deliver cholesterol to cells is almost never true because every cell can make all the cholesterol it needs. In an emergency, any cell can upregulate LDL receptors to pull in LDLs if needed, but this rarely happens.
If LDLs bring cholesterol back to the liver, or if drugs induce LDL receptor expression, LDL cholesterol levels in plasma can be lowered extremely low. A prevalent belief that lowering LDL cholesterol too much will deprive the brain and injure it will be addressed later. The peripheral system refers to anything outside the brain, and the brain lipid and lipoprotein system has almost nothing to do with plasma transportation of lipids and lipoproteins.
Plasma is the major highway of the body (with the lymphatic system as another route). Plasma is water with proteins such as hemoglobin in red blood cells. Water-soluble substances like glucose and ions (sodium, potassium, chloride) transport easily without carriers. Steroidal hormones like testosterone or cortisol are virtually all bound to carriers such as albumin or sex hormone binding globulin, with only a slight free fraction.
Cholesterol requires carriers called lipoproteins, which consist of lipids on the inside (repelling water) and proteins on the outside (soluble in water). The apoA family has nothing to do with Lp(a), which is a totally different apolipoprotein.
ApoA particles vastly outnumber apoB particles, but because apoA particles are much smaller, total cholesterol carrying capacity is much greater in the apoB family. On a lipid panel showing total cholesterol of 200 mg/dL, LDL plus VLDL cholesterol might total 140 mg/dL while HDL cholesterol might be only 60 mg/dL.
When LDL cholesterol goes down, total cholesterol also decreases. There is less need for cholesterol to return to the liver because cells are in cholesterol balance and effluxing less cholesterol. HDLs transfer less cholesterol to LDLs. The system remains operational with all components communicating through nuclear transcription factors. Lower LDL cholesterol means less cholesterol returning to the liver, but there is no need for cholesterol to return because balance exists across all cells.
The amount of cholesterol in plasma is much smaller than total body cholesterol stores. Most cholesterol in the body is within cells of peripheral organs including the liver, skin, and every membrane of every cell. The brain has its own separate cholesterol component because the brain and peripheral systems do not interact.
In plasma, not all circulating cholesterol is within lipoproteins. Red blood cells are the biggest carrier of cholesterol in the bloodstream because they are cells with cell membranes and are vastly larger than lipoproteins. Red blood cells carry more milligrams of cholesterol than lipoproteins. There is no free cholesterol in plasma, only a minuscule amount on albumin.
The brain has 20 times more cholesterol than the liver. The brain contains approximately 20 to 25 grams of cholesterol, while total body cholesterol is approximately 140 grams and the liver contains 3 to 5 grams. The brain holds onto cholesterol tightly, whereas the liver functions as a handling station or transfer station that sends cholesterol out or excretes it into bile through bile acids or as free cholesterol. The liver maintains only a small pool of cholesterol to perform its functions.
If peripheral cholesterol goes down by 50 to 75 percent (for example, total cholesterol falling from 200 to 100 mg/dL), total body cholesterol has fallen by only a couple of percent because plasma cholesterol represents a tiny fraction of total body stores.
Atherosclerotic disease is the leading global killer. If atherosclerosis is present, there is cholesterol buildup in the artery wall. Without cholesterol buildup in the artery wall, atherosclerosis does not exist. Cholesterol does not accumulate because arteries oversynthesize it. Cholesterol enters artery walls from plasma lipoproteins.
Every clinical trial and Mendelian randomization analysis shows that the more cholesterol is lowered, the fewer atherosclerotic events occur. ApoB-containing lipoproteins (beta lipoproteins) carry most cholesterol in the bloodstream. When apoB particles (primarily LDLs due to their long residence time) exceed a certain threshold concentration, they enter the artery wall through simple diffusion. Endothelial dysfunction facilitates entry but particles enter even healthy artery walls once concentration thresholds are exceeded.
Once apoB particles enter the artery wall, they become trapped, aggregate, and oxidize. The immune system sends white blood cells that engulf them, creating cholesterol-laden macrophages called foam cells that aggregate to form plaque. There is one apoB molecule per particle, so apoB concentration measurement indicates particle number. When apoB levels exceed certain thresholds, atherosclerosis becomes very likely.
The main driver of apoB concentration is defective clearance from plasma due to insufficient LDL receptor expression on the liver. When apoB particles are not cleared, they invade artery walls. Every apoB particle that enters the liver is one less entering an artery wall.
LDL cholesterol has been used for decades as a surrogate for apoB particle number. VLDL cholesterol can be estimated as triglycerides divided by five. The vast majority of particles entering artery walls are LDLs. Increasing LDL receptor expression or recycling increases clearance and lowers apoB.
Not all individuals with elevated apoB or LDL cholesterol above the physiologic threshold develop disease at the same rate. Some individuals with LDL cholesterol of 160 mg/dL and total cholesterol over 200 mg/dL reach age 90 without heart attacks despite smoking, while others with identical lipid profiles have heart attacks at age 51. Factors influencing this heterogeneity include metabolic health, insulin resistance, type 2 diabetes, chronic inflammation, endothelial cell damage, blood pressure, smoking, autoimmune diseases, rheumatoid arthritis, collagen diseases, and oxidative processes. Atherosclerosis development is an incredibly slow process taking decades, supporting the principle that lower is better and longer is better for maintaining low apoB.
Some protective factors remain unidentified even with genetic testing. Polygenic risk scores can predict who will reach age 80 without heart attacks by examining multiple genetic factors simultaneously. Genes control outcomes, and some individuals are genetically blessed with protective mechanisms. However, an LDL cholesterol of 200 mg/dL does not guarantee protection, and assuming one is an exception carries significant risk.
The brain has the greatest storage source of cholesterol in the body. The question of whether the brain relies on peripheral cholesterol remains to be addressed.
The brain's cholesterol content and storage has zero relationship to plasma cholesterol levels. Certain lipoproteins can cross into the brain, but apo B-containing particles that carry the vast majority of cholesterol cannot cross the blood-brain barrier because they are too large.
During the second and third trimesters in utero, the fetal brain begins de novo cholesterol synthesis because it will need substantial cholesterol for cell membranes. The brain likely contains more cell membranes than any other tissue combined, making cholesterol essential for neuronal function. At birth, maternal cholesterol contribution ceases entirely, and the brain produces all its own cholesterol.
Brain cells consist of neurons and three types of glial cells: astrocytes (major cholesterol producers in adults), oligodendrocytes, and microglia. Oligodendrocytes produce approximately 70% of brain cholesterol because cholesterol is required to create myelin sheaths around axons and dendrites.
Every brain cell overproduces cholesterol from birth because the brain anticipates growth. Between birth and age 10, the brain expands to adult size and requires massive cholesterol quantities for membranes. Children at age 2 may have LDL cholesterol as low as 30 mg/dL during peak brain growth, demonstrating that physiologic circulating cholesterol levels have no bearing on brain development.
Around age 10, when adult brain size is reached, cholesterol synthesis readjusts. Oligodendrocytes continue production. Microglia reduce output. Astrocytes maintain high production. However, neurons cease cholesterol synthesis entirely and begin relying on astrocytes to supply cholesterol. This shift occurs because cholesterol synthesis requires 37 enzymatic steps and consumes over 30 ATP molecules per cholesterol molecule synthesized. Neurons, being the most metabolically active brain cells due to continuous action potentials and synaptic activity, conserve ATP by outsourcing cholesterol production.
Cholesterol transport between brain cells occurs through brain interstitial tissue called the matriosome rather than blood. Astrocytes synthesize cholesterol via a pathway involving desmosterol as the penultimate sterol before conversion to cholesterol. They package cholesterol with APOE protein to form lipoproteins secreted into the matriosome.
Brain lipoproteins have the density and buoyancy of plasma HDL particles but differ fundamentally in protein composition. Plasma HDLs contain multiple copies of apo A1, whereas brain HDLs contain multiple copies of APOE. These particles mature in the matriosome as cholesterol esters move to the particle core.
Neurons express LDL receptors to internalize APOE-containing lipoproteins. The LDL receptor recognizes APOE in the brain because no apo B-containing lipoproteins exist there. The receptor should more accurately be called the APOB/APOE receptor since it binds both proteins. Neurons also express LDL receptor-related protein 1 (LRP1), which has exclusive affinity for APOE, and scavenger receptor B1, which recognizes APOE-containing particles.
The LDL receptor binds lipoproteins through electrostatic interactions between its apo recognition domain and the LDL receptor binding domain on apo B or APOE. Proper conformation of these domains determines clearance efficiency. Small and large LDL particles often exhibit reduced clearance because their apo B conformation impairs receptor recognition. LDL receptors function as dimers, with two receptors simultaneously binding two LDL particles.
The liver clears VLDLs and chylomicrons primarily via LRP1, which recognizes APOE. These particles carry multiple APOE copies per particle, unlike LDLs which carry one apo B copy. In the brain, neurons use LRP1 as the primary APOE-clearing receptor, with LDL receptors and scavenger receptor B1 providing additional uptake capacity.
Two pathways produce cholesterol with different penultimate sterols: the desmosterol pathway and the lathosterol pathway. In peripheral tissues, the vast majority of cholesterol synthesis proceeds through the lathosterol pathway, with desmosterol pathway activity limited primarily to steroidogenic tissues. In the brain before age 10, neuronal cholesterol synthesis uses the lathosterol pathway. After age 10, when neurons stop synthesizing cholesterol, astrocyte production uses the desmosterol pathway exclusively under normal conditions.
Desmosterol measured in plasma correlates highly with cerebral spinal fluid desmosterol and brain tissue desmosterol, making it a useful marker of brain cholesterol synthesis. Lathosterol cannot serve this purpose because 95% of plasma lathosterol originates from peripheral cells.
The APOE gene exists in three alleles (E2, E3, E4), producing six possible genotypes: E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, and E4/E4. Each genotype produces a distinct APOE protein isoform differing by single amino acid substitutions that alter protein conformation and binding properties.
Population frequencies approximate: E3/E3 at 55%, E3/E4 at 20-25%, E4/E4 at 1-2%, E2/E3 at 2-3%, with E2/E2 and E2/E4 being rarest. E3/E3 represents the wild-type reference. E3/E4 genotype confers approximately 2-3 times higher Alzheimer's disease risk compared to E3/E3. E4/E4 genotype confers 8-12 times higher risk.
HDL particles perform functions unrelated to cholesterol transport, including roles in the innate immune system, inflammation regulation, infection defense, and cancer modulation. Over 200 proteins have been identified on HDL particles, though individual particles carry only one or two peptides alongside apo A1 and apo A2. The smallest, densest HDL particles (discoidal HDLs consisting of apo A1 alone) have minimal lipid content and highest density.
Extremely small HDL particles containing apo A1, either free or bound to accessory proteins, can cross the blood-brain barrier into the matriosome. Brain cells cannot synthesize apo A1. These particles likely cross via receptor-mediated transport, possibly involving scavenger receptor B1 at the blood-brain barrier. Once in the brain, these peripheral apo A1-containing particles bind to APOE-containing brain HDL particles, potentially transferring antioxidant and anti-inflammatory proteins into the brain's lipid transport system.
Brain HDL particles exist in different subpopulations. Some contain only APOE, while others include APO A1 along with APOE. When APO A1 is present, additional proteins associated with it may provide beneficial effects within the brain. In the periphery, functional HDL particles exist alongside dysfunctional HDL particles that carry improper proteins or lack necessary proteins, leading to harmful effects on tissues. No clinical blood test currently exists to distinguish functional from dysfunctional HDL.
When an individual carries the APOE4 genotype, astrocytes produce APOE4 peptides that assemble into brain HDL particles. These APOE4-containing particles behave similarly to dysfunctional APOE in the periphery. APOE4 HDL particles exhibit reduced binding affinity to neuronal receptors compared to APOE3 or APOE2 particles. This impaired binding disrupts cholesterol transport into neurons, resulting in insufficient cholesterol delivery to neuronal cell membranes.
Neurons incorporate cholesterol directly into cell membranes. Proper membrane cholesterol balance is critical because amyloid precursor protein (APP) resides within these membranes. When cholesterol levels are imbalanced, beta and gamma secretases cleave APP to generate beta-amyloid, particularly the more toxic amyloid-beta 42 isoform. With adequate cholesterol, alpha secretase predominates, favoring production of the less toxic amyloid-beta 40 isoform. This mechanism represents one pathway through which APOE4 contributes to Alzheimer's disease risk.
Autopsy studies of Alzheimer's disease patients reveal cholesterol-overloaded brain tissue, particularly within neurons. Neuronal function depends on cell membrane integrity; proper membrane cholesterol composition enables correct signaling and synaptic firing. Excessive membrane cholesterol promotes beta and gamma secretase activity, increasing amyloid-beta 42 production. Insufficient cholesterol disrupts membrane function and signaling.
Neurons are the only brain cells capable of eliminating cholesterol. The brain retains cholesterol with a half-life of approximately five years, compared to a few days in peripheral tissues. Excess cholesterol within neurons is toxic, disrupting membrane function and crystallizing in the cytosol, leading to neuronal death. Neurons convert cholesterol to 24S-hydroxycholesterol via the enzyme 24S-hydroxycholesterolase. This oxysterol gains a hydroxy group at carbon 24 in addition to the existing oxygen at carbon 3, increasing water solubility.
24S-hydroxycholesterol diffuses out of neurons and crosses the blood-brain barrier. At the barrier, fatty acids and phospholipids create a transient tunnel allowing passage into plasma, where it binds rapidly to albumin or circulating lipoproteins. These carriers transport it to the liver. The liver expresses the same enzyme and converts cholesterol to oxysterols that ultimately form bile acids for fecal excretion. This represents the brain's primary route for eliminating excess cholesterol.
When excess cholesterol accumulates in neuronal membranes, cytosolic cholesterol decreases and 24S-hydroxycholesterol production declines. Plasma 24S-hydroxycholesterol levels serve as a biomarker of brain cholesterol homeostasis; elevated levels indicate the brain is attempting to offload excess cholesterol and signal neuronal stress. Researchers developing Alzheimer's disease therapies monitor this marker, expecting effective interventions to reduce plasma 24S-hydroxycholesterol. Desmosterol represents another measurable biomarker of brain cholesterol synthesis. While desmosterol testing is commercially available, no clinical laboratory currently offers 24S-hydroxycholesterol testing outside research settings.
APOE4 particles show markedly reduced clearance through neuronal LDL receptors and lysosomal pathways. Cholesterol may transfer into the neuronal membrane upon particle contact, but fails to reach the cytosol efficiently. This creates a complex lipid trafficking defect in APOE4 carriers.
Among lipid-lowering drug classes, only statins cross the blood-brain barrier and influence brain cholesterol synthesis. All other agents (PCSK9 inhibitors, bempedoic acid, ezetimibe, bile acid sequestrants, CETP inhibitors) act peripherally without brain penetration. Both lipophilic and hydrophilic statins ultimately reach the brain in steady state, though lipophilic agents may enter more readily. All statins inhibit HMG-CoA reductase within the brain to varying degrees once steady-state concentrations are achieved.
Meta-analyses of statin trials demonstrate either neutral or reduced incidence of Alzheimer's disease and cognitive impairment. No trials show statins causing brain injury. Because cholesterol accumulation is neurotoxic, modest reduction of brain cholesterol synthesis may be beneficial. However, excessive suppression risks neurologic symptoms such as brain fog, which typically resolve upon statin discontinuation. Alzheimer's disease develops over decades, so modest long-term suppression may be tolerable, particularly in APOE4 carriers or those with family history.
Plasma desmosterol correlates strongly with cerebrospinal fluid desmosterol levels. Individuals with low desmosterol exhibit higher rates of cognitive impairment and Alzheimer's disease. Monitoring plasma desmosterol during statin therapy allows assessment of whether brain cholesterol synthesis has been oversuppressed. If levels drop excessively, statin dose reduction or substitution with non-brain-penetrant agents (such as ezetimibe) may be considered while still achieving APOB reduction.
Statin therapy reduces plasma 24S-hydroxycholesterol levels, consistent with decreased brain cholesterol synthesis. This reduction may be desirable in patients at risk for Alzheimer's disease, but must be balanced against desmosterol levels to avoid oversuppression.
Ezetimibe inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestine. Its glucuronide metabolite crosses the blood-brain barrier in small amounts. Animal studies indicate this metabolite inhibits hexokinase and reduces glycosylation of brain proteins, potentially lowering inflammation. Neurologists report anecdotal cognitive benefits in patients receiving ezetimibe alongside APOB-lowering therapy. Because ezetimibe does not cross the blood-brain barrier itself, any central effects are attributed to the glucuronide metabolite.
Both EPA and DHA are important for brain function, with DHA present in greater quantities, though EPA contributions are increasingly recognized. Humans cannot synthesize omega-3 fatty acids and must obtain them from diet. Dietary and supplemental omega-3s are delivered primarily as triglycerides or phospholipids. Krill oil provides omega-3s in phospholipid form. Pancreatic lipase hydrolyzes triglycerides and phospholipids to release free fatty acids for absorption.
Pancreatic lipases cleave fatty acids from triglyceride or phospholipid vehicles. Free EPA or DHA joins with other lipids in biliary micelles and is absorbed via the fatty acid transporter CD36. A lysophospholipid can also be absorbed. When one fatty acid is removed from a phospholipid, the resulting lysophospholipid is a smaller molecule that is easily absorbed. Lipases produce either free fatty acids or lysophospholipids, and if the remaining fatty acid on a lysophospholipid is an omega-3, it is absorbed.
Once inside the enterocyte, the cell immediately resynthesizes the fatty acids into a full phospholipid or attaches them to a triglyceride molecule. Triglycerides go into the core of the chylomicron while phospholipids go onto the surface. Chylomicrons enter the lymphatics and rapidly reach plasma. They undergo rapid hydrolysis at muscle and fat cells by lipases, freeing the phospholipids.
Phospholipids cannot circulate freely in the bloodstream. They bind to phospholipid transfer protein, which carries either full phospholipids or lysophospholipids. This delivery mechanism transports omega-3s to the blood-brain barrier, where a specific receptor internalizes the lysophospholipid form of DHA or EPA. Once inside the brain, the fatty acids can be trafficked in brain HDL particles or enter the cytosol of the first cell encountered.
The vehicle of ingestion does not appear to matter significantly for absorption. Users should verify that supplements contain the stated amount of omega-3s, as label accuracy cannot be assumed for every product.
In the periphery, a large trial showed that EPA may be more important than DHA for lessening residual risk in people with well-controlled apoB. Once omega-3s reach the brain, both EPA and DHA are required. Some individuals can convert EPA to DHA, but not everyone can. Omega-3 concentrations are high in the brain relative to other tissues and are integral to cell membrane health.
Observational data link higher omega-3 index values to improved brain function and reduced neurological issues. Studies by Bill Harris associate omega-3 content with brain size in regions such as the hypothalamus. An academic standard would require level-one randomized, blinded, controlled trials; such trials are largely absent for brain outcomes. Low omega-3 index is associated with sudden death and increased atherosclerotic heart disease. One trial demonstrated benefit from EPA in insulin-resistant, high-risk patients with well-controlled apoB.
Observational evidence supports an omega-3 index of 8–9% as sufficient for proper membrane incorporation throughout the body. No randomized trial establishes a specific brain benefit at 10% versus 8–9%, but there is little downside to aiming higher when no harm is demonstrated.
CETP loss-of-function genetic variants are associated with reduced Alzheimer’s disease and cognitive impairment. Pharmacologic CETP inhibition with obicetrapib is being investigated for the same effect. In the BROADWAY trial, obicetrapib was administered primarily to lower apoB and reduce major adverse cardiovascular events. The trial also measured Alzheimer’s biomarkers, including phosphorylated tau, the amyloid 40/42 ratio, and fibrillary markers, all of which moved in a favorable direction.
CETP inhibitors produce large HDL particles carrying multiple copies of apoA1. The liver senses reduced free apoA1 and increases hepatic production of apoA1. Elevated plasma apoA1 can bind protective proteins and generate small, protein-rich HDL species capable of crossing the blood-brain barrier. These particles may deliver anti-inflammatory and antioxidative proteins into the brain. ApoA1 can also bind to dysfunctional apoE4-containing brain HDL particles and potentially restore their function.
Further cognitive, imaging, and PET studies are planned. Alzheimer’s biomarkers may eventually reduce reliance on PET scanning. The drug’s primary FDA indication will be apoB reduction, but additional data on cognitive outcomes, especially in apoE4 carriers, are anticipated. No safety signals have halted trials to date, but the agent is not yet FDA approved.
Optimal patient selection and intervention timing are critical. Enrolling high-risk individuals, particularly apoE4 carriers, before advanced pathology develops increases the likelihood of detecting benefit. The PREDIMED trial demonstrated that a Mediterranean diet intervention in a primary-prevention population halted early due to clear superiority over a low-fat diet, illustrating the value of intervening at the right disease stage.
The discussion covered distinctions between peripheral and brain cholesterol metabolism, the roles of oligodendrocytes and neurons, apoE versus apoA1 pathways, and the plausibility of therapeutic strategies targeting brain HDL function. Lipids remain a rapidly evolving field with ongoing opportunities for further exploration.
Keep Peter Attia MD in your library
Save the videos and channels worth coming back to, and find them again in one place.
